Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®
RegulatoryapprovedUbeslo®Evlarco®Positive
AI Analysis
Summary
NewAmsterdam Pharma and Menarini Group received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib/ezetimiba combination), a first-in-class drug supported by Phase 3 BROADWAY trial data.
Clinical Trial Data
Phase
3
Outcome Details
European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib/ezetimiba fixed-dose combination)
Importance:9/10
Sentiment:
0.95
regulatory approvalEuropefirst-in-classobicetrapibezetimiba combination
Related Companies
Read the original article
Published by PR Newswire Biotech on September 23, 2026 5:43 PM